524 related articles for article (PubMed ID: 27217001)
41. Synthesis, Molecular Docking Study and in vitro Anticancer Activity of Tetrazole Linked Benzochromene Derivatives.
Gorle S; Maddila S; Maddila SN; Naicker K; Singh M; Singh P; Jonnalagadda SB
Anticancer Agents Med Chem; 2017; 17(3):464-470. PubMed ID: 27357544
[TBL] [Abstract][Full Text] [Related]
42. Green synthesis and anticancer potential of chalcone linked-1,2,3-triazoles.
Yadav P; Lal K; Kumar A; Guru SK; Jaglan S; Bhushan S
Eur J Med Chem; 2017 Jan; 126():944-953. PubMed ID: 28011424
[TBL] [Abstract][Full Text] [Related]
43. Design and Synthesis of Aspirin-chalcone Mimic Conjugates as Potential Anticancer Agents.
Mohamed-Ezzat RA; Srour AM
Anticancer Agents Med Chem; 2024; 24(7):544-557. PubMed ID: 38204260
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents.
Burmaoglu S; Ozcan S; Balcioglu S; Gencel M; Noma SAA; Essiz S; Ates B; Algul O
Bioorg Chem; 2019 Oct; 91():103149. PubMed ID: 31382060
[TBL] [Abstract][Full Text] [Related]
45. In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons.
Cabrera M; Mastandrea I; Otero G; Cerecetto H; González M
Bioorg Med Chem; 2016 Apr; 24(8):1665-74. PubMed ID: 26970663
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents.
Ayati A; Esmaeili R; Moghimi S; Oghabi Bakhshaiesh T; Eslami-S Z; Majidzadeh-A K; Safavi M; Emami S; Foroumadi A
Eur J Med Chem; 2018 Feb; 145():404-412. PubMed ID: 29335206
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds.
El-Meligie S; Taher AT; Kamal AM; Youssef A
Eur J Med Chem; 2017 Jan; 126():52-60. PubMed ID: 27744186
[TBL] [Abstract][Full Text] [Related]
48. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
49. Linked parallel synthesis and MTT bioassay screening of substituted chalcones.
Lawrence NJ; Rennison D; McGown AT; Ducki S; Gul LA; Hadfield JA; Khan N
J Comb Chem; 2001; 3(5):421-6. PubMed ID: 11549359
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents.
Kumar SK; Hager E; Pettit C; Gurulingappa H; Davidson NE; Khan SR
J Med Chem; 2003 Jul; 46(14):2813-5. PubMed ID: 12825923
[TBL] [Abstract][Full Text] [Related]
51. Bis-chalcone analogues as potent NO production inhibitors and as cytotoxic agents.
Vijaya Bhaskar Reddy M; Shen YC; Ohkoshi E; Bastow KF; Qian K; Lee KH; Wu TS
Eur J Med Chem; 2012 Jan; 47(1):97-103. PubMed ID: 22115618
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and Evaluation of Heterocycles Based Chalcone Derivatives as Antiproliferative Agents.
Çavuşoğlu BK; Atlı Ö; Görmüş G; Özkay Y; Kaplancıklı ZA
Anticancer Agents Med Chem; 2018; 18(7):1044-1053. PubMed ID: 29308744
[TBL] [Abstract][Full Text] [Related]
53. Biological evaluation of polycyclic chalcone based acrylamides in human MCF-7 and HeLa cancer cell lines.
Gunasekaran V; Yuvakkumar R; Ganesan R; Palapetta SC; Gurusamy H
Environ Res; 2023 Apr; 222():115395. PubMed ID: 36731601
[TBL] [Abstract][Full Text] [Related]
54. Chalcone-benzoxaborole hybrids as novel anticancer agents.
Zhang J; Yang F; Qiao Z; Zhu M; Zhou H
Bioorg Med Chem Lett; 2016 Dec; 26(23):5797-5801. PubMed ID: 28327308
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of New Arylidene 2,5-Diketopiperazines and Evaluation of their Anti-Acetylcholinesterase, Anti-xanthine Oxidase, Anti-diabetic and Cytotoxic Activities.
Belkacem MA; Jannet HB; Ferhout H; Mzali L; Bouajila J
Med Chem; 2017; 13(8):744-752. PubMed ID: 28480832
[TBL] [Abstract][Full Text] [Related]
56. Anti-tumorigenic chalcones.
Shibata S
Stem Cells; 1994 Jan; 12(1):44-52. PubMed ID: 8142919
[TBL] [Abstract][Full Text] [Related]
57. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents.
Alafeefy AM; Ashour AE
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):541-5. PubMed ID: 21851213
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and biological evaluation of chalcone acetamide derivatives against triple negative breast cancer.
Kumar P; Singh R; Sharma D; Hassan QP; Gopu B; Anal JMH
Bioorg Med Chem Lett; 2024 Jul; 107():129795. PubMed ID: 38750906
[TBL] [Abstract][Full Text] [Related]
60. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
